Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of the tryptophan-rich allosteric network and sodium egress in GPCR activation.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Molecular Design with Artificial Intelligence: Progress and Perspectives for Small Molecules.

Chemical reviews·2026
Same author

DiffBreed: automatic differentiation enables efficient gradient-based optimization of breeding strategies.

Bioinformatics (Oxford, England)·2025
Same author

Harnessing Explainable AI to Explore Structure-Activity Relationships in Artificial Olfaction.

ACS applied materials & interfaces·2025
Same author

GPepT: A Foundation Language Model for Peptidomimetics Incorporating Noncanonical Amino Acids.

ACS medicinal chemistry letters·2025
Same author

Molecule Graph Networks with Many-Body Equivariant Interactions.

Journal of chemical theory and computation·2025

Related Experiment Video

Updated: Jul 13, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Mining complex genotypic features for predicting HIV-1 drug resistance.

Hiroto Saigo1, Takeaki Uno, Koji Tsuda

  • 1Max Planck Institute for Biological Cybernetics, 72076 Tübingen, Germany.

Bioinformatics (Oxford, England)
|August 19, 2007
PubMed
Summary

Predicting human immunodeficiency virus type 1 (HIV-1) drug resistance requires considering mutation associations. Itemset boosting effectively identifies these crucial mutation combinations for accurate genotype-based pharmacotherapy predictions.

More Related Videos

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
11:10

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

Published on: December 27, 2010

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach
07:06

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

Related Experiment Videos

Last Updated: Jul 13, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3
11:10

Genotypic Inference of HIV-1 Tropism Using Population-based Sequencing of V3

Published on: December 27, 2010

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach
07:06

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

Area of Science:

  • Computational biology
  • Genomics
  • Drug discovery

Background:

  • HIV-1 drug resistance emerges from mutations, complicating treatment.
  • Predicting resistance from genotype data is vital for personalized pharmacotherapy.
  • Mutation associations, not just individual mutations, significantly impact drug resistance.

Purpose of the Study:

  • To develop a method that accurately predicts HIV-1 drug resistance by considering mutation associations.
  • To explicitly identify salient mutation combinations influencing drug resistance.

Main Methods:

  • Itemset boosting performs linear regression on all possible mutation combinations (power sets).
  • A forward feature selection with branch-and-bound search efficiently identifies key mutation combinations.
  • The method explicitly reveals significant mutation associations.

Main Results:

  • Itemset boosting accurately predicts drug resistance, particularly for nucleotide reverse transcriptase inhibitors (NRTIs).
  • The method successfully identified known biologically relevant mutation associations.
  • It outperforms methods that cannot account for mutation interactions.

Conclusions:

  • Itemset boosting is a powerful tool for predicting HIV-1 drug resistance by modeling mutation associations.
  • This approach enhances the design of effective, individualized pharmacotherapies.
  • The method provides explicit insights into the genetic basis of drug resistance.